Effectiveness and safety of empagliflozin‐based quadruple therapy compared with insulin glargine‐based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice

This open‐label, prospective study evaluated the effectiveness and safety of empagliflozin as add‐on therapy in inadequately controlled type 2 diabetes (T2D) patients (glycated haemoglobin [HbA1c], 7.5‐12%) who were already using three other types of orally active antidiabetic agents. A total of 268...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2019-01, Vol.21 (1), p.173-177
Main Authors: Ku, Eu Jeong, Lee, Dong‐Hwa, Jeon, Hyun Jeong, Oh, Tae Keun
Format: Article
Language:English
Subjects:
Antidiabetics
Blood pressure
Body weight
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
empagliflozin
Hemoglobin
Insulin
Observational studies
Patients
quadruple combination antidiabetic agent
SGLT2 inhibitor
type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This open‐label, prospective study evaluated the effectiveness and safety of empagliflozin as add‐on therapy in inadequately controlled type 2 diabetes (T2D) patients (glycated haemoglobin [HbA1c], 7.5‐12%) who were already using three other types of orally active antidiabetic agents. A total of 268 T2D patients were enrolled and divided into two groups, empagliflozin (EMPA 25 mg/d, n = 142) or insulin glargine (INS, n = 126), respectively. After the treatment period of 24 weeks, HbA1c and fasting plasma glucose (FPG) were significantly reduced (HbA1c, P = 0.004; FPG, P = 0.008, respectively) in the EMPA group compared to the INS group. Also, EMPA treatment evoked a significant reduction in body weight (P 
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.13476